ABSTRACT
Objective Determine the clinical safety and feasibility of implementing a telemedicine and medication delivery service (TMDS) to address gaps in nighttime healthcare access for children in low-resource settings.
Methods We implemented a TMDS in Haiti called ‘MotoMeds’: (i) A parent/guardian of a child ≤10 years contacted the call center (6pm-5am). (ii) A provider used paper clinical decision support tools to triage the case as mild, moderate, or severe. Severe cases were referred to emergency care. For non-severe cases, call center providers gathered clinical findings to generate an assessment and plan. (iii) For households within the delivery zone, a provider and driver were dispatched with medications/fluids; the provider performed a paired in-person exam. For households outside the delivery zone, the family received phone consult alone. All families received a follow-up call at 10-days. Data were analyzed for clinical safety and feasibility.
Results A total of 391 cases were enrolled from September 9th, 2019 to January 19th, 2021; 89% (347) received a household visit. Most cases were triaged as mild or moderate (92%; 361). Among the severe cases, 83% (20) sought subsequent referred care. The most common complaint was a respiratory problem (63%; 246). At 10-days, 95% (329) of parents reported their child’s condition as “improved” or “recovered”. Ninety-nine percent (344) rated the TMDS as “good” or “great”. The median phone consultation was 20 minutes, time to arrival at the household was 73 minutes and total workflow per case was 114 minutes.
Conclusion The TMDS was a feasible healthcare delivery model with high rates of improved clinical status at 10-days.
Study registration (clinicaltrials.gov) NCT03943654
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03943654
Funding Statement
This work was supported by the National Institutes of Health grants to EJN [DP5OD019893] and internal support from the Emerging Pathogens Institute, the Departments of Pediatrics, the Department of Environmental and Global Health, and the Department of Emergency Medicine at the University of Florida.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was ethically approved by the Comité National de Bioéthique (National Bioethics Committee of Haiti; 1819-51) and the Institutional Review Board at University of Florida (IRB201802920).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
